Ionis Reports Fourth Quarter and Full Year 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Rubrik (RBRK) Tops Q2 EPS by 16c, Beats on Revenue; Offers FY27 EPS Guidance
Ionis Pharmaceuticals (IONS) PT Raised to $57 at Stifel
February 28, 2018 6:39 AM ESTStifel raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $57.00 (from $55.00) while maintaining a Hold rating.
Analyst Stephen Willey notes SPINRAZA royalties highlight increasing leverage, with IONIS-HTTRx data now on deck.
... More